Changes in peripheral mitochondrial DNA copy number in metformin-treated women with polycystic ovary syndrome: a longitudinal study

Changes in peripheral mitochondrial DNA copy number in metformin-treated women with polycystic ovary syndrome: a longitudinal study

Blog Article

Abstract Background Patients with polycystic ovarian syndrome (PCOS) are associated with known alterations in mitochondria DNA copy number (mtDNA-CN).The aim of this study is to study the change in mtDNA-CN in patients with PCOS who were treated with metformin.Methods This is a prospective cohort of patients with PCOS, who received metformin for one year.From 2009 to 2015, 88 women diagnosed with PCOS, based on the Rotterdam criteria, were enrolled.Serial measurements of mtDNA-CN, 8-hydroxydeoxyguanosine (8-OHdG), anthropometric, metabolic, endocrine, and inflammatory markers were obtained before and after 3, 6, and 12 months of Kelp treatment.

Results A significant decrease in mtDNA-CN was seen over the course of one year.Other markers, including 8-OHdG, KWAN LOONG OIL testosterone, free androgen index, blood pressure and liver enzymes, also decreased in the same interval.On regression analysis, there was a significant association between the change in mtDNA-CN and serum total testosterone, and no association between mtDNA-CN and metabolic factors.Conclusions Treatment with metformin is associated with a time-dependent decrease in mtDNA-CN in patients with PCOS who are treated over the course of one year.This may signify a reduction in mitochondria dysfunction.

The change in mtDNA-CN corresponds to a similar change in serum total testosterone, and suggests a possible relationship between mtDNA-CN and testosterone.Trial registration ClinicalTrials.gov , NCT00172523.Registered September 15, 2005.